Aaberg-Jessen et al. 22 found that co-expression of TIMP-1 and CD63 have effects in glioblastoma stemness and contribute to the poor prognosis of patients through influencing tumor aggressiveness and resistance of therapy. This evidence concerns the gene CD63 and neoplasm.